Cargando…

Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021

Detalles Bibliográficos
Autores principales:	Hause, Anne M., Gee, Julianne, Johnson, Tara, Jazwa, Amelia, Marquez, Paige, Miller, Elaine, Su, John, Shimabukuro, Tom T., Shay, David K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2021
Materias:	Full Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368750/ https://www.ncbi.nlm.nih.gov/pubmed/33956781 http://dx.doi.org/10.15585/mmwr.mm7018e3

Ejemplares similares

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021
por: Shay, David K., et al.
Publicado: (2021)

Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults
por: Tompkins, Lindsay K., et al.
Publicado: (2022)

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021
por: Gee, Julianne, et al.
Publicado: (2021)

Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US
por: Hause, Anne M., et al.
Publicado: (2022)

Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe
por: Rosenblum, Hannah G, et al.
Publicado: (2022)

TTS with Janssen's COVID-19 vaccine
Publicado: (2021)

Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years — United States, May 17–July 31, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5–11 Years — United States, October 12–January 1, 2023
por: Hause, Anne M., et al.
Publicado: (2023)

Anxiety disorders with Janssen's COVID-19 vaccine
Publicado: (2021)

Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021
por: Oliver, Sara E., et al.
Publicado: (2022)

COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months–5 Years — United States, June 18, 2022–August 21, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Janssen COVID-19 vaccine-related tinnitus and dizziness
Publicado: (2021)

PRAC: blood clots with Janssen's COVID-19 vaccine
Publicado: (2021)

Syndrome VITT : le vaccin Janssen également concerné ?
por: Manus, Jean-Marie
Publicado: (2021)

Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status — United States, January 12, 2022–March 28, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021–February 2022
por: Woo, Emily Jane, et al.
Publicado: (2023)

Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system
por: Chapin-Bardales, Johanna, et al.
Publicado: (2021)

Safeguarding against use of contaminated COVID-19 Vaccine Janssen
Publicado: (2021)

L’EMA recommande le vaccin monodose de Janssen
por: Dalmat, Yann-Mickael
Publicado: (2021)

English-only labels for Janssen's COVID-19 vaccine in Canada
Publicado: (2021)

FDA limits authorised use of Janssen COVID-19 vaccine
Publicado: (2022)

Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
por: MacNeil, Jessica R., et al.
Publicado: (2021)

U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines
por: Gubernot, Diane, et al.
Publicado: (2021)

Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
por: Oliver, Sara E., et al.
Publicado: (2021)

Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020–January, 2022: an observational cohort study
por: Wong, Karen K, et al.
Publicado: (2022)

Warning for Janssen COVID-19 vaccine: risk of Guillain-Barré syndrome
Publicado: (2021)

Janssen/Johnson & Johnson COVID-19 vaccine-related GBS in USA
Publicado: (2021)

FDA and CDC recommend resuming use of Janssen COVID-19 vaccine
Publicado: (2021)

The v-safe after vaccination health checker: Active vaccine safety monitoring during CDC’s COVID-19 pandemic response
por: Myers, Tanya R., et al.
Publicado: (2023)

Magnetic Janssen effect
por: Thorens, L., et al.
Publicado: (2021)

COVID-19 Vaccine Janssen: rare unusual blood clots, low platelets
Publicado: (2021)

A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine
por: Lospinoso, Kristen, et al.
Publicado: (2021)

Editorial April 2021
por: Spires-Jones, Tara L
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nq3s2c4sfa34smrhcvkp9ki6i3